Importance of Vascular Endothelial Growth Factor (VEGF) for Metastatic Dissemination of Adenoid Cystic Carcinoma of Salivary Glands
Authors:
J. Hoza; I. Stárek; M. Brož; Richard Salzman
Authors‘ workplace:
Klinika otorinolaryngologie a chirurgie hlavy a krku LF UP a FN v Olomouci
Published in:
Otorinolaryngol Foniatr, 63, 2014, No. 3, pp. 188-192.
Category:
Original Article
Overview
Adenoid cystic carcinoma (ACC) is one of relatively common malignant salivary tumors. It is characterized by slow, but relenteless progression with proclivity to late hematogenous dissemination. Lymphogenous spread of salivary ACC is rare. However, in some cases nodal metastases may go undetected for many years. Recently, there is growing clinical and experimental evidence, that the growth and spread of some tumors via blood and lymphatic vessels is associated with the production of various factors. Among them, family of vascular endothelial growth factor (VEGF) is considered to be most crucial. Hematogenous and lymphogenous metastasis are promoted with VEGF-A/B and VEGF-C/D, respectively, which are produced by tumor cells. Here we present a literature overview of up to now published studies, confirming the role of VEGF in progression and hematogenous spread of salivary ACC. The importance of this factor for lymphangiogenic dissemination of that histopathologic entity is not clear, mainly because of limited number of studies published so far.
Keywords:
vascular endothelial growth factor (VEGF), adenoid cystic carcinoma, salivary gland, metastasis
Sources
1. Argiris, A., Ghebremichael, M., Burtness B. et al.: A phase 2 trial of bortezomib followd by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinom of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer, 117, 2011, s. 3374-3382.
2. Armstrong, J. G., Harrison, L. B., Thaler, H. T., Friedlander – Klar, H., Fass, D. E., Zelefsky, M. J., Shah, J. P., Strong, E. W., Spiro, R. H.: The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer, 69,1992, s. 615-619.
3. Audet, N., Beasly, N. J., MacMillan, C., Jackson, D. G., Gullane, P. J., Kamel-Reid, S.: Lymphatic vessel density, nodal metastasis, and prognosis in patients with head and neck cancer. Arch. Otolaryngol. Head Neck Surg., 131, 2005, s. 1065-1070.
4. Beasly, N. J., Prevo, R., Banerji, S., Leek, R. D., Leek, R. D., Moore, J., van Trappen, P., Cox, G., Harris, A. L., Jackson, D. G.: Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res., 62, 2002, s. 1315-1320.
5. Burian, M., Quint, C., Neuchrist, C.: Angiogenic factors in laryngeal carcinomas: do they have prognostic relevance? Acta Otolaryngol., 119, 1999, s. 289-292.
6. Cao, Y.: Opinion: Emerging mechanism of tumour lymphangiogenesis and lymphatic metastasis. Nat. Rev. Cancer, 5, 2005 s. 735-743.
7. El-Naggar, A. K., Huvos, A. G.: Adenoid cystic carcinoma. WHO classification of tumours: pathology & genetics. In: Barnes, E. L., Eveson, J. W., Reichart, P., Sidransky, D.: Head and neck tumours. Lyon, IARC Press, 2005, s. 221-222.
8. Fujita, G., Sato S., Kishino, M., Iwai, S., Nakazawa, M., Toyosawa, S., Yura, Y., Ogawa, Y.: Lymphatic vessels and related factors in adenoid cystic carcinoma of the salivary gland. Mod. Pathol., 24, 2011, 7, s. 885-891.
9. Gerwins, P., Sköldenberg, E., Claesson-Welsh, L.: Function of fibroblast growth factor and vascular endothelial factors and their receptors in angiogenesis. Hepatology, 34, 2000, s. 185-194.
10. Heinrich, M., Joensuu, H., Demetri, G. et al.: Phase II, Open-label study evaluating the activity of Imatinib in treating life-threatening malignancies known to be associated with Imatinib-sensitive tyrosine kinases. Clin. Cancor, 14, 2008, s. 2717-2725.
11. Hotte, S. J., Winquist, E. W., Lamont, E., MacKenzie, M., Vokes, E., Chen, E. X., Brown, S., Pond, G. R., Murgo, A.,Siu, L. L.: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J. Clin. Oncol., 23, 2005, s. 585-590.
12. Hu. W. G., Li, J. W., Feng, B., Beveridge, M., Yue, F., Lu, A. G., Ma, J. J., Wang, M. L., Guo, Y., Jin, X. L., Zheng, M. H.: Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis. Eur. Surg. Res., 39, 2007, s. 229-238.
13. Chau, N. E. X., Chen, E., Hotte, J. et al.: A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann. Oncol., 23, 2012, s.1562-1570.
14. Chen, A. M., Garcia, J., Lee, N. Y., Bucci, M. K., Eisele, D. W.: Pattern of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary gland: what is the role of elective neck irradiation? Int. J. Radiat. Oncol. Biol. Phys., 67, 2007, s. 988-994.
15. Choi, W. W., Lewis, M. M., Lawson, D., Yi-Goen, Q., Birdsong, G. G., Cotsonins, G. A., Cohen, C., Young, A.: Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod. Pathol., 18, 2005, s. 143-152.
16. Inoue, K., Ozeki, Y., Sugunuma, T., Sugiura, Y., Tanaka, S.: Vascular endothelial growth factor expression in primary esophageal squamous carcinoma. Association with angiogenesis and tumor progression. Cancer, 79, 1997, s. 206-213.
17. Kawata, R., Koutetsu, L., Yoshimura, K., Nishikawa, S., Takenaka, H.: Indication for elective neck dissection for N0 carcinoma of the parotid gland: a single institution´s 20-year experience. Acta Oto-Laryngol., 130, 2010, s. 286-292.
18. Kitadai, Y., Amioka, T., Haruma, K., Tanaka, S., Yoshihara, M.,Sumii, K., Matsutani, N., Yasui, W., Chayama, K.: Clinico-pathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int. J. Cancer, 93, 2001, s. 662-666.
19. Klener, P.: Nové možnosti využití bevacizumabu v protinádorové léčbě. Remedia, 18, 2008, s. 70–75.
20. Kyzas, P. A., Geleff, S., Batistatou, A., Agnantis, N. J.: Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J. Pathol., 206, 2005, s. 170-177.
21. Laurie, S. A., Licitra, L.: Systemic therapy in the palliative management of advanced salivary gland cancers. J. Clin. Oncol., 24, 2006, s. 2673-2678.
22. Li, J., Nong, X., Chen, Q., Yang, Y., Li, J., Li. Y.: Nerve growth factor and vascular endothelial growth factor: retrospective analysis of 63 patients with salivary adenoid cystic carcinoma. Int. J. Oral Sci., 2, 2010, s. 35-44.
23. Lim, J. J., Kang, S., Lee, M. R., Pai, H. K., Yoon H. J., Lee, J. I., Hong, S. P., Lim, Ch. B.: Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, K-67 and prognosis. J. Oral Pathol. Med., 32, 2003, s. 552-561.
24. Matilla, M. M. T., Ruohola, J. K., Karpanen, T., Jackson, D. G., Alitalo, K., Härkönen, P.: VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int. J. Cancer, 98, 2002, s. 946-951.
25. Mello, M. F., Costa, A. F., Freitas, L. L., Soares, A. B,. Araujo, V. C., Tincani, A. J., Martins, A. S., Alemani, A.: Lymphatic vessel density and expressions of lymphangiogenic growth factors in salivary carcinomas. Neoplasma, 58, 2011, s. 331-336.
26. Mineta, H., Miura, K., Ogino, T., Takebayashi, S., Misawa, K., Ueda, Y., Suzuki, I., Dictor, M., Borg, A., Wennerberg, J.: Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br. J. Cancer, 83, 2000, s. 775-781.
27. Nathanson, S. D.: Insights into the mechanism of lymph node metastasis. Cancer, 98, 2003, s. 413-423.
28. O-charoenrat, P., Rhys-Evans, P., Eccles, S. A.: Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer, 92, 2001, s. 556-568.
29. Pepper, M. S., Tille, J. C., Nisato, R., Skobe, M.: Lymphangiogenesis and tumor metastasis. Cell Tissue Res., 314, 2003, s. 167-177.
30. Salven, P., Lymboussaki, A., Heikkila, P., Jääskela--Saari, H., Enholm, B., Aase, K., Euler, G., Eriksson, U.,Alitalo, K., Joensuu, H.: Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Amer. J. Pathol., 153, 1998, s. 103-108.
31. Seethala, R. R., Hunt, J. L., Baloch, Z. W., LiVolsi, V. A., Barnes, E. L.: Adenoid cystic carcinoma with high-grade transformation. A report of 11 cases and a review of the literature. Amer. J. Surg. Pathol., 31, 2007, s. 1686-1694.
32. Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R.,Janes, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K., Detmar, M.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med., 2, 2001, s. 192-198.
33. Soares, A. B., Juliano, P. B., Araújo, V. C., Altemani, A.: Lymphatic vascular density and lymphagiogenesis during tumor progression of carcinoma ex pleomorphic adenoma. J. Clin. Pathol., 60, 2007, s. 995-1000.
34. Stacker, S. A., Caesar, C., Baldwin, M. E., Thornton, G. E., Williams, R. A., Prevo, R., Jackson D. G., Nishikawa, S. I., Kubo, H., Achen M. G.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med., 2001, 7, s. 186-191.
35. Stacker, S. A., Achen, M. G., Jussila, L., Baldwin, M. E., Alitalo, K.: Lymphangiogenesis and cancer metastasis. Nat. Rev. Cancer, 2, 2002, s. 573-583.
36. Stárek, I., Kučerová, L., Skálová, A., Brož, M., Bakaj, M., Langová, K.: Imunohistochemická exprese C-kit onkoproteinu u karcinomů slinných žláz. Otorinolaryng. Foniat. /Prague/, 59, 2010, s. 129-135.
37. Tang, Q. L., Chen, W. L., Tan, X. Y., Li, H, G., Yuan, X. P., Fan, S., Wen, B., Song, Y.: Expression and significance of Cyr61 in distant cells of human primary salivary adenoid cystic carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 112, 2011, s. 228-236.
38. Teymoortash, A., Werner, J. A.: Value of neck dissection in patients with cancer of the parotid gland and a clinical N0 neck. Onkologie, 25, 2002, s. 122-126.
39. Teymoortash, A., Schrader, C., Shimoda, H., Kato, S., Werner, J. A.: Evidence of lymphangiogenesis in Warthin´s tumor of the parotid gland. Oral. Oncol., 43, 2007, s. 614-618.
40. Tsurusaki, T., Kanda, S., Sakai, H., Saito, Y., Alitalo, K., Koji, T.: Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br. J. Cancer, 80, 1999, s. 309-313.
41. Umeda, M., Komatsubara, H., Nishimatsu, N., Oku, N., Shibuya, Y., Yokoo, S., Komori, T.: Establishment and characterization of a human adenoid cystic carcinoma line of the salivary gland which is serially transplantable and spontaneously metastasises to the lung in nude mice. Oral. Oncol., 38, 2002, s. 30-34.
42. Witte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell P., Bohlen, P.: Monoclonal antibodies targeting the VEGF receptor-2 (Flk-1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev., 17, 1998, s. 155-161.
43. Woolger, J. A., Triantafullou, A.: Contemporary salivary clinical pathology. Facts and dilemmas. In: Salivary gland disorders and diseases: Diagnosis and management. Chpt. 4, s. 27-41. Eds. Bradley PJ, Guntinas-Lichius O. Thieme 2011, Stuttgart, ISBN 978-3-13-146491-0.
44. Xu, W., Liu, L. Z., Loizidou, M., Ahmed, M., Charles, I. G.: The role of nitrid oxid in cancer (review). Cell Res., 12, 2002, s. 311-320.
45. Xu, W. G., Ji, X. R., Zhou, L. X., Xie, Y. Q., Zhang, L. F.: Prognostic value of VEGF in primary oesophageal squamous cell carcinoma. Chin. J. Cancer Res., 16, 2004, s. 85-89.
46. Yamazaki, Y., Morita, T.: Molecular and functional diversity of vascular endothelial growth factors. Molecular Diversity, 10, 2006, s. 515-527.
47. Younes, M. N., Park, Y. W., Yazici, Y. D., Gu, M., Santi-llan, A. A., Nong, X., El-Naggar, A. K., Myers, J. N.: Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Molecular Target Therapeutics, 5, 2006, s. 2696-2705.
48. Zhang, J., Peng, B.: In vitro angiogenesis and expression of nuclear factor κB and VEGF in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma. BMC Cancer, 7, 2007, s. 95-111.
Labels
Audiology Paediatric ENT ENT (Otorhinolaryngology)Article was published in
Otorhinolaryngology and Phoniatrics
2014 Issue 3
Most read in this issue
- Therapy of Percentual Hearing Loss by Rheohemapheresis – First Experience
- Facial (Craniofacial) Epitheses
- Effects of Lactoflora Administered Nasally: Results of a Primary Study
- Importance of Vascular Endothelial Growth Factor (VEGF) for Metastatic Dissemination of Adenoid Cystic Carcinoma of Salivary Glands